Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Clinical trial NCT06322342 · COMPLETED

Trial details

NCT number: NCT06322342
Sponsor: Reveal Pharmaceuticals Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Central Nervous System (CNS) Lesions Brain Metastases Brain Neoplasms Brain Neoplasms, Benign Brain Tumor, Primary Brain Tumor, Recurrent Brain Tumors Brain Cancer Brain Tumor Brain Neoplasm, Primary Multiple Sclerosis Multiple Sclerosis Brain Lesion

Start date: 2024-08-15
Primary completion: 2025-12-19
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.